Adjuvant cemiplimab is associated with a significant reduction in the risk of disease recurrence in patients with high-risk CSCC after surgery and postoperative radiotherapy, according to results from the double-blind, phase 3 C-POST trial (Abstract 6001).

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.

NIVOPOSTOP results show that adding nivolumab to standard adjuvant chemoradiotherapy after surgery significantly improves DFS in patients with high-risk locally advanced head and neck squamous cell carcinoma regardless of PD-L1 expression (LBA2).

Adding atezolizumab to standard FOLFOX chemotherapy significantly improves disease-free survival in patients with stage III deficient DNA mismatch repair colon cancer, and yields a 50% reduction in the risk of recurrence and death versus chemotherapy alone, according to results from the phase 3 ATOMIC trial (LBA1).

According to phase 1 results from the TROPION-Lung02 trial, datopotamab deruxtecan (Dato-DXd) plus pembrolizumab both with and without platinum chemotherapy is reasonably well tolerated and produces durable antitumor activity in the first-line setting in patients with advanced non–small cell lung cancer (Abstract 8501).